Abstract
The author agrees with a previous paper by Drs. Bloom and Boesen that antiestrogens are valuable in treatment of breast cancer. However he stresses that if a time gap between therapy and nafoxidine treatment is not allowed the response which follows may merely be due to the rebound effect of with drawing endocrine therapy. The author feels his data are more comprehensive because he gives 3 clearly defined groups rather than 2. Both tamoxifen and nafoxidine show a 42% rate of partial response or complete tumor regression. He concludes that for the primary management of soft tissue breast cancer (as opposed to skeletal metastases) tamoxifen (or nafoxidine) is being prescribed in preference to the standard hormonal agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
